Patent Strategy for Startups

Whether a startup should file a patent depends heavily on the type of technology, the competitive landscape, and the startup's stage. The clearest cases for filing: (1) The core technology can be reverse-engineered from the product — if a competitor can buy your product, reverse-engineer it, and replicate your innovation, a patent is your only meaningful protection; (2) The startup is in hardware, medical devices, biotech, pharma, or deep tech — sectors where patents are the expected and primary competitive moat; (3) Investors are involved or being courted — many investors (especially those in deep tech, medtech, and pharma) will not invest without a patent strategy in place; (4) The founder has a genuinely novel technical invention — not just a new application of well-known techniques. Cases where patents may not be the priority: (1) The competitive advantage is execution, distribution, or network effects, not the technology itself — most successful consumer social apps were not patented; (2) The technology changes fast and the product will be obsolete before a patent issues (18–30 months); (3) The runway is 6–12 months and there are better uses of limited capital. The most common mistake: founders who are building hardware or biotech startups who wait 2–3 years to file a patent application, by which point competitors have filed, prior art has accumulated, or the founders have made public disclosures that complicate the application. For hardware, file a provisional as soon as the core technology is defined — even if the product is unfinished.

The least expensive credible path to establishing patent protection: (1) Provisional patent application + micro entity status: a provisional application costs $83 in USPTO fees for micro entity applicants (individuals with low income and fewer than 4 prior patent filings). A basic provisional drafted with attorney assistance typically costs $2,000–$5,000. This provides a 12-month priority date window — time to validate, raise funds, and prepare a full application. Do NOT file a self-drafted provisional without attorney input: a provisional that doesn't adequately describe the invention will fail to support the non-provisional claims, wasting the priority date. (2) Patent Pro Bono Program: if your household income is at or below 300% of the federal poverty line (~$93,000 for a family of four in 2024), you may qualify for free patent prosecution through the USPTO's Patent Pro Bono Program, administered through law school clinics. Apply at the USPTO website. (3) Small entity status: if your company has fewer than 500 employees and hasn't assigned rights to a large entity, you automatically qualify for small entity status — 50% off all USPTO fees. (4) Use continuations wisely: instead of filing multiple independent applications, file a series of continuations from a single well-drafted parent application — one attorney fee for the parent, lower fees for continuations. (5) Focus your patent on the most commercially important claims: don't draft 40 claims covering hypothetical embodiments — focus on the 5–10 claims that directly cover the commercial product. Quality beats quantity, especially on a startup budget. Total cost estimate for a provisional + non-provisional utility patent through grant (small entity): $8,000–$20,000 including attorney fees and USPTO fees over 2–3 years.

A Proprietary Information and Inventions Assignment Agreement (PIIA, sometimes called a CIIA — Confidential Information and Inventions Assignment Agreement) is a contract between the company and each employee (including founders) that: (1) Assigns all inventions and work product created by the employee within the scope of their employment (and related to the company's business) to the company; (2) Obligates the employee to maintain company confidential information as a secret; (3) Covers prior inventions (the employee discloses any prior inventions they are carving out from the assignment); (4) May include a non-solicitation clause (varies by jurisdiction). Without PIIAs: each inventor personally owns their inventions. Under US patent law, inventorship is an individual right — the patent is owned by the inventor unless the inventor assigns it in writing (35 U.S.C. § 261). If founders build the core technology before signing PIIAs and assigning to the company, the company may not own its own core IP. This is a fatal issue in VC fundraising and M&A: investors will require that all IP is cleanly owned by the company entity. Investors and acquirers routinely conduct IP due diligence specifically to verify that PIIAs were signed before key inventions were made. When to sign: PIIAs should be signed at or before the date of first employment — and for co-founders, at or before the date of incorporation. A retroactive PIIA signed after the invention was made may be enforceable, but creates a period of ambiguous ownership that is a red flag in due diligence. Note: several states (California, Delaware, North Carolina, Minnesota, Washington, Illinois) have statutes limiting the scope of employee invention assignment clauses — the PIIA cannot require assignment of inventions made entirely on the employee's own time, using the employee's own resources, that do not relate to the company's business and were not made using the company's resources (California Labor Code § 2870). A well-drafted PIIA complies with these statutory limits.

If a startup founder developed the core technology while employed by or enrolled at a university that receives federal funding, the Bayh-Dole Act (35 U.S.C. §§ 200-212) and university IP policies may give the university ownership rights over the invention. This is one of the most complex and high-stakes IP issues for university spinouts. How it typically works: (1) University IP policies: most research universities require faculty, staff, and graduate students to assign inventions made using university resources (equipment, funding, facilities) to the university's technology transfer office (TTO); (2) Bayh-Dole: for federally funded research (NSF, NIH, DARPA, DoE grants), the Bayh-Dole Act allows universities to retain title but requires disclosure to the federal agency and grants the government a nonexclusive license; (3) License from the university: the founder/spinout typically licenses (or occasionally has the university assign) the patents from the TTO — this is the normal path for university spinouts. What to do: (1) Disclose the invention to the university's TTO BEFORE incorporating the startup or commercializing anything — delay in disclosure can constitute a breach of the university employment/enrollment agreement; (2) Negotiate a license from the TTO to the spinout company — TTO licenses often include royalties (typically 1–5% of net sales), equity in the spinout (typically 1–5%), and milestone payments; (3) Review the university IP policy carefully — some universities have adopted policies favorable to student inventors (e.g., MIT's policy gives students ownership of most course-project inventions); (4) Get IP legal counsel early — the structure of the TTO license, the treatment of government IP rights, and the assignment of royalty rights between founders are all complex questions that require specialized legal advice. Mistakes here can result in the university claiming ownership after the startup has raised significant funding.

Investors — especially those in deep tech, biotech, medtech, and hardware — conduct IP due diligence as part of their investment process. Key items in patent due diligence: (1) Chain of title: are all inventions assigned from every inventor (founder, employee, contractor, academic collaborator) to the company? Are PIIAs signed by everyone who contributed to the technology? Is the chain unbroken from inventor → company? (2) Prior employer IP claims: do any founders have prior employment agreements that could claim rights in the inventions? Any pre-existing employment-era inventions that were not carved out? (3) Pending or granted patents: are applications filed? What are the priority dates? Are the claims broad enough to be commercially valuable? What is the prosecution status? (4) Freedom-to-operate: has the company assessed whether its product practices any third-party patents? Are there blocking patents that could limit commercialization? (5) Pre-filing disclosures: has the technology been publicly disclosed before the priority date? Are there publications, conference presentations, or public demos that predate the patent filing and create prior art problems? (6) Contractor and collaborator IP: has code, hardware design, or other IP been contributed by parties who have not signed IP assignment agreements? (7) International IP: if the company has international commercial ambitions, are there international filings or a PCT pending? (8) Trade secrets: does the company have adequate non-disclosure agreements and confidentiality policies protecting know-how and trade secrets? What investors want to see: a clear, unambiguous IP ownership structure with PIIAs for all contributors, one or more patent applications with solid priority dates and commercially relevant claims, no known blocking third-party IP, and a credible IP strategy for the next 3–5 years.